Tumor hierarchy of breast cancer cells can be potential cause for drug resistance

Reviewed by Emily Henderson, B.Sc.Aug 25 2020

You might have heard the old proverb, "It takes a village to raise a child."

University of Cincinnati instructor Syn Yeo, PhD, thinks the same analogy applies when it comes to cells and the growth of cancer, particularly breast cancer.

In his recent study, published in the journal eLife, Yeo, research instructor in the department of cancer biology at the UC College of Medicine and co-lead author, says it can take cells in different forms or "life stages" to cause cancer to grow and spread.

Our recent findings emphasize the need to account for the specific cell states that are present within a tumor. This could potentially help determine the combination of drugs that are required to eliminate all the cell states that are present to eliminate treatment resistance."

Syn Yeo, PhD, University of Cincinnati instructor

Yeo is a member in the lab of Jun-Lin Guan, PhD, the Francis Brunning Endowed Chair and professor of cancer biology. Yeo says that when it comes to breast cancers, it is known that cells within a tumor are varied.

"This diversity poses a problem to treating patients because particular subsets of tumor cells may be drug resistant and eventually lead to disease recurrence," he says. "One of the factors contributing to this diversity is the fact that tumor cells can exist in different cellular states, ranging from more stem-like cells that can become other cell types to more differentiated cells that have been coded to serve a purpose, or do a certain 'job' within the system.

"Cancer cells with stem-like properties are known to cause drug resistance, and they are generally seen as being at the top of the tumor hierarchy, like the king or queen of the village, with more differentiated tumor cells towards the bottom of the hierarchy, like the common townspeople."

In this study, researchers used breast cancer animal models to determine tumor hierarchies beyond "ruler" and "common people" cells, Yeo says. They identified and categorized singular cells which helped them understand each, individual cell's purpose. Yeo adds that bulk tumor cell analysis would have masked the cellular details.

"We were able to find a complex spectrum of cell states between different tumor types that can range from stem-cells to the 'beginner cells' to more differentiated cells," he says. "In our village [scenario], these would be the governors and mayors, followed by the common townspeople. Furthermore, depending on the lineage of the tumor, some may show a spectrum of cell states that are higher up in the hierarchy and vice versa.

"These findings are important because they show we need to know more about how these specific cell states contribute to tumor growth so we can target them with combination drug therapies, potentially helping more people who may otherwise experience drug resistance."